

# Broad Clinical Development Program for Cobimetinib

As of our Q1 2017 financial results call, May 1, 2017; for a full list of ongoing studies, please visit [clinicaltrials.gov](http://clinicaltrials.gov).

Indication	Combination Regimen	Status Update
<b>Metastatic or Unresectable Locally Advanced Melanoma</b>		
BRAF mutation-positive	+ vemurafenib	Approved in US, EU and other territories
First-line BRAF mutation-positive	+ atezolizumab + vemurafenib	Phase 3 (IMspire150 TRILOGY) began enrolling Q1 2017
First-line BRAF wild-type	+ atezolizumab	Phase 3 (IMspire170) expected to begin enrolling Q2 2017
<b>Colorectal Cancer</b>		
Third-line advanced or metastatic disease	+ atezolizumab	Phase 3 (IMblaze370) completed enrollment in Q1 2017
Second/third-line metastatic disease	+ atezolizumab + bevacizumab	Phase 1
<b>Breast Cancer</b>		
First-line metastatic triple negative disease	+ taxane +/- atezolizumab	Phase 2 (COLET)